Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.

Can Urol Assoc J

Division of Urology, London Health Sciences Centre, Division of Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON.

Published: November 2013

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879740PMC

Publication Analysis

Top Keywords

low-dose rate
4
rate brachytherapy
4
brachytherapy patients
4
patients low-
4
low- intermediate-risk
4
intermediate-risk prostate
4
prostate cancer
4
cancer systematic
4
systematic review
4
low-dose
1

Similar Publications

Analysis of the effect of platelet function and different doses of ticagrelor after flow diverter treatment of intracranial aneurysms.

Neurosurg Rev

January 2025

Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Ticagrelor has become the standard drug for the treatment of intracranial aneurysms (IAs) with flow diverters (FDs), but the dosage has not been standardized. The effect of platelet function on clinical and imaging prognosis remains unclear. This study aimed to show the effects of different doses of ticagrelor and platelet aggregation function on the clinical and imaging prognosis after FDs treatment of aneurysms.

View Article and Find Full Text PDF

Purpose: This study evaluates the feasibility of utilizing robotic-assisted bronchoscopy with cone beam computed tomography (RB-CBCT) platform to perform low-dose-rate brachytherapy implants (LDR-BT) in a mechanically ventilated human cadaveric model. Post-implant dosimetry was compared to standard stereotactic body radiation therapy plans (SBRT).

Materials And Methods: The RB-CBCT platform was used to place inert LDR-BT seeds into mechanically ventilated human cadavers with percutaneously injected pseudotumors.

View Article and Find Full Text PDF

Essential Thrombocythemia: A Review.

JAMA

January 2025

CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.

Importance: Essential thrombocythemia, a clonal myeloproliferative neoplasm with excessive platelet production, is associated with an increased risk of thrombosis and bleeding. The annual incidence rate of essential thrombocythemia in the US is 1.5/100 000 persons.

View Article and Find Full Text PDF

Background: Low-dose computed tomography screening reduces lung cancer-specific mortality in high-risk individuals. Lung cancer risk factors overlap with comorbid diseases, highlighting the significance of frailty and comorbidities for lung cancer screening (LCS). Here, we describe the prevalence of frailty and comorbidity in those invited for LCS and evaluate their associations with response to telephone risk assessment invitation and subsequent uptake of LCS.

View Article and Find Full Text PDF

Introduction: Lung cancer screening (LCS) using low-dose-computed tomography reduces lung cancer mortality in high-risk individuals. Evaluating and monitoring LCS programs are important to ensure and improve quality, efficiency and participant outcomes. There is no agreement on LCS quality indicators (QIs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!